Clinical Trials
95 trialsBEACON
University of Birmingham
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NICE
Fundació Sant Joan de Déu
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Milton S. Hershey Medical Center
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Milton S. Hershey Medical Center
METRO-NB2012
University of Cologne
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Racotumomab in Patients With High-risk Neuroblastoma
Laboratorio Elea Phoenix S.A.
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
N2011-01
New Approaches to Neuroblastoma Therapy Consortium
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Children's Oncology Group
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
University of Iowa
RIST-rNB-2011
University of Regensburg
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Children's Oncology Group
PEPI
Baylor College of Medicine
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Memorial Sloan Kettering Cancer Center
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Memorial Sloan Kettering Cancer Center
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
Memorial Sloan Kettering Cancer Center
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
Memorial Sloan Kettering Cancer Center
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
Children's Oncology Group
Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma
Samsung Medical Center
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation
University of Michigan Rogel Cancer Center
N2007-01: Ultratraceâ„¢ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Molecular Insight Pharmaceuticals, Inc.
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Children's Oncology Group
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation
Samsung Medical Center
MIITOP
Centre Oscar Lambret
TOTEM2
Gustave Roussy, Cancer Campus, Grand Paris
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
National Cancer Institute (NCI)
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
Children's Oncology Group
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Dana-Farber Cancer Institute